Has clinical trial permission for Category 1 of Therapeutic Biological drugs for the treatment of "granulocytopenia and thrombocytopenia after tumor chemoradiotherapy"

Clinical trial approvals for new indications of "tumor immunotherapy" and "tumor combination therapy" are being applied

High expression quantity of KLT-1101 cell line

Stable pilot process

Up to 99% purity and 20% better activity than international standards

Has applied for 8 national major invention patents. Among them, 4 have been authorized and 4 have been applied for and made public;

The invention patent (ZL03148180.9) "therapeutic agent and composition for restoring hematopoietic function and its use" is the world's latest cutting-edge technological invention at the same scientific research level and research and development stage as the United States.